Project Details

Description

BAXERNA 2.0 will establish a new vaccine development pipeline based on dramatically improved immunopeptidomics screening
and innovative mRNA vaccine formulation. We will use our powerful new pipeline to develop novel mRNA vaccines against three
bacterial pathogens that can persist within phagocytic cells: Mycobacterium tuberculosis (MTB), Mycobacterium ulcerans (MU), and
Acinetobacter baumannii (AB).
AcronymEUAR135
StatusActive
Effective start/end date1/07/2330/06/28

Keywords

  • Biochemistry and molecular biology
  • Infectious diseases
  • Tuberculosis
  • clinical trial

Flemish discipline codes in use since 2023

  • Human health engineering

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.